Wealth Enhancement Advisory Services LLC acquired a new stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 19,260 shares of the company’s stock, valued at approximately $28,000.
Other hedge funds have also recently bought and sold shares of the company. Gilead Sciences Inc. purchased a new position in Allogene Therapeutics during the fourth quarter worth $2,464,000. Charles Schwab Investment Management Inc. increased its position in Allogene Therapeutics by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,188,838 shares of the company’s stock worth $2,532,000 after buying an additional 9,990 shares in the last quarter. Cibc World Markets Corp purchased a new position in Allogene Therapeutics during the fourth quarter worth $26,000. Two Sigma Advisers LP increased its position in Allogene Therapeutics by 12.1% during the fourth quarter. Two Sigma Advisers LP now owns 2,702,200 shares of the company’s stock worth $5,756,000 after buying an additional 291,800 shares in the last quarter. Finally, DAFNA Capital Management LLC increased its position in Allogene Therapeutics by 18.1% during the fourth quarter. DAFNA Capital Management LLC now owns 1,240,118 shares of the company’s stock worth $2,641,000 after buying an additional 190,000 shares in the last quarter. 83.63% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on ALLO shares. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price target on shares of Allogene Therapeutics in a research report on Friday, March 14th. Royal Bank Of Canada reissued an “outperform” rating and set a $10.00 price target on shares of Allogene Therapeutics in a research report on Wednesday, May 14th. Robert W. Baird dropped their price target on Allogene Therapeutics from $12.00 to $9.00 and set an “outperform” rating for the company in a research report on Wednesday, May 14th. Citizens Jmp downgraded Allogene Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 14th. Finally, Oppenheimer lowered their price objective on Allogene Therapeutics from $10.00 to $9.00 and set an “outperform” rating for the company in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Allogene Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $8.44.
Allogene Therapeutics Stock Up 1.6%
Shares of NASDAQ:ALLO opened at $1.28 on Friday. The company has a market cap of $279.97 million, a P/E ratio of -1.04 and a beta of 0.31. Allogene Therapeutics, Inc. has a 52 week low of $0.86 and a 52 week high of $3.78. The business has a fifty day simple moving average of $1.23 and a 200-day simple moving average of $1.60.
Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.28) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.28). Sell-side analysts expect that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.
Allogene Therapeutics Profile
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
Featured Stories
- Five stocks we like better than Allogene Therapeutics
- Stock Market Upgrades: What Are They?
- The Meteoric Rise of Rocket Lab: A Space Stock to Watch
- What Are Trending Stocks? Trending Stocks Explained
- 3 Hot Tech Stocks Showing Bullish Price Action Right Now
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Meta and Autonomous Advertising: The Stock’s Next Big Tailwind?
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.